Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, introduces an ongoing Phase I trial (NCT04577326) investigating the safety of ATA2271 in treating advanced mesothelioma. ATA2271 is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets mesothelin, which is overexpressed in many solid tumors. ATA2271 incorporates novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies, which results in reduced T cell exhaustion and improved functional persistence. These technologies are also utilized in ATA3271, an allogeneic equivalent of ATA2271 being developed that leverages Atara’s EBV T-cell platform. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.
Pascal Touchon is the President & CEO of Atara Biotherapeutics, San Francisco, CA.